Search

everythinglearnresearchcommunity

for

Search:↓

A trial showed that a new treatment is safe and effective for male pattern baldness, with most participants growing new hair.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.

The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.

Aumolertinib effectively controls lung cancer and improves quality of life.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Guselkumab significantly improves psoriasis symptoms within 12 weeks.

The data suggests that dosing differences can help manage spasticity in patients with upper motor neuron dysfunction.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

The treatment is safe and effective for elderly patients with advanced non-small-cell lung cancer.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

The trial is testing if a helmet that uses light can prevent hair loss during chemotherapy.

AMP-303 safely increases hair growth in men with hair loss.

Elagolix did not effectively treat polycystic ovary syndrome.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

Using a call center to collect data in a trial for eye disease in diabetics led to high response rates and very little missing information.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Upadacitinib effectively treats severe alopecia areata and is safe.

TAK-279 effectively reduces psoriasis symptoms and is safe.

ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.